Speaking with Stat ahead of his exit, Robert Califf expressed concern about the potential for brain drain in government. Other news is on promising drugs for lung cancer patients, the upcoming J.P.

WuXi Biologics grants exclusive global rights of trispecific t-cell engager to Candid Therapeutics: Shanghai Wednesday, January 8, 2025, 15:00 Hrs [IST] WuXi Biologics, a leading ...

China's WuXi Biologics has announced plans to sell its vaccine facility in Ireland to U.S. pharmaceutical giant Merck & Co.

According to the Korea Exchange on the 8th, as of 9:22 a.m., Samsung Biologics was trading at 1 million and 1,000 won, up ...

WuXi upgraded its WuXiBody platform in bispecific antibody discovery to address the growing global demand for these complex ...

Health-care companies rose as a reported U.S. death from bird flu stoked fears of a new pandemic, boosting shares of vaccine makers.

Current health news includes Trump considering protective measures for gas appliances against regulatory changes. The WHO ...

JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth ...

The Department of Defense added dozens of firms as ‘Chinese military entities’ in register on January 7, stoking steep stock ...

WuXi AppTec, the Shanghai-based biotech giant, has sold its South Philly-based WuXi Advanced Therapies contract manufacturing ...

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a ...